You are here: Industry Insights > Market News

News List

New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs PharmaSources
June 05, 2024
New research showes that biotechs can save more than 30% in costs, halve start-up times, and cut risk with CROs that have in-house scientific and regulatory affairs.
Vetter Wins Best Managed Companies Award 2024 PharmaSources
May 30, 2024
Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), has once again been awarded the Best Managed Companies Award, marking its fifth consecutive win.
ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development PharmaSources
May 30, 2024
ModeX will harness the power of ProBioGen's pioneering DirectedLuck® Transposase Technology, which enables the production of high-titer, stable expression cell lines that are critical to the success of ModeX's antibody program.
New CRO Focused on Cannabis-based Drug Trials Launched PharmaSources
May 23, 2024
Cannovation Clinical Research Partners takes a holistic approach to assist businesses throughout the entire product lifecycle, encompassing product development, commercialization, and launch phases.
InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma PharmaSources
May 21, 2024
The first patient has been dosed in a clinical trial of the Company's BCL2 inhibitor, ICP-248, in combination with orelabrutinib as a first-line therapy for chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL) in China.
Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA PharmaSources
May 17, 2024
The expanded collaboration includes increasing adoption of the NVIDIA Clara suite of AI-powered computing platforms, software, and services in the Sartorius ecosystem.
InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis PharmaSources
May 16, 2024
InnoCare announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.
Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification PharmaSources
May 14, 2024
The life science group Sartorius is collaborating with biopharmaceutical company Sanofi to develop an end-to-end platform for integrated and continuous downstream bioprocessing.
Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template PharmaSources
May 10, 2024
Nucleic Acid Medicines Manufacture, Round 2 call.
First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ. PharmaSources
May 09, 2024
The first commercial manufacturing run of LYFGENIA – a one-time gene therapy for the treatment of sickle cell disease developed by bluebird bio – was performed at its Allendale, NJ site.